Search results for: tocilizumab

Don’t Forget the Host: COVID-19 Cytokine Storm

Randy Q. Cron, MD, PhD, & W. Winn Chatham, MD | March 16, 2020

The new coronavirus outbreak, COVID-19, reminds us how we have struggled to keep ahead of mutating pathogens through the ages.

Pediatric Cases Require Special Considerations & Aggressive Treatment Plans

Thomas R. Collins | March 12, 2020

ATLANTA—Managing pediatric patients with rheumatic disease involves special considerations, such as developmental concerns and physiological traits that may affect dosing of medications, according to two experts. During a session at the 2019 ACR/ARP Annual Meeting, Courtney Kremer, ARNP, a pediatric nurse practitioner at the University of Iowa Stead Family Children’s Hospital, Iowa City, and Jessica…

FDA Update: New Drug Approvals, New & Expanded Indications, & More

Susan Bernstein | March 12, 2020

ATLANTA—New drug approvals, new and expanded drug indications, and important safety and other updates relevant for rheumatologists were presented by three physicians from the U.S. Food & Drug Administration (FDA) on Nov. 11 at the 2019 ACR/ARP Annual Meeting. New JAK Inhibitor Approved for RA On Aug. 16, 2019, the FDA approved upadacitinib (Rinvoq), an…

Thoughtful Pediatric Care: Pediatric Cases Require Special Considerations & Aggressive Treatment Plans

Thomas R. Collins | March 9, 2020

In Canada, five provinces will now reimburse patients with plaque psoriasis who use risankizumab. Also, Canada Health has approved apremilast for treating adults with plaque psoriasis and psoriatic arthritis…

Pearls & Myths: Experts Offer Advice & Dispel Myths

Thomas R. Collins | February 25, 2020

GCA, GPA, myositis, new research—rheumatology care keeps clinicians on their toes & requires them to stay up to date…

FDA Rheumatology Update: New Drug Approvals, Plus Expanded Drug Indications & Safety Concerns

Susan Bernstein | February 12, 2020

Last year, the FDA was busy with new biologic and other drug approvals, new and expanded drug indications, and important safety updates relevant to rheumatology…

Varicella Zoster Virus Not Associated with Giant Cell Arteritis Pathogenesis

Carina Stanton | February 4, 2020

Researchers suggest antiviral therapy is not appropriate for patients with GCA, based on their study findings and related research…

Update on the Management of Takayasu Arteritis

Lara C. Pullen, PhD | February 4, 2020

A rare form of large vessel vasculitis, Takayasu arteritis persents with no clear patterns, with patients experiencing vascular symptoms, as well as such systemic symptoms as fever and weight loss. A systematic literature review found evidence to guide rheumatologists in monitoring and treating their patients with Takayasu arteritis…

New Insights into the Management of Giant Cell Arteritis

Lara C. Pullen, PhD | January 28, 2020

A systematic literature review identified novel evidence on the treatment and management of GCA that was incorporated into the most recent EULAR recommendations on the management of large vessel vasculitis. Investigators confirmed the efficacy of prompt initiation of glucocorticoids and found fast-track approaches to diagnosis lowered the risk of ischemic complications…

Case Report: Obliterative Bronchiolitis in Rheumatoid Arthritis

Robin Paudel, MD, Prerna Dogra, MD, & Richard S. Morehead, MD | January 17, 2020

A 59-year-old woman with rheumatoid arthritis (RA) presented to our pulmonary clinic for progressively worsening dyspnea of five years’ duration. She described progressively worsening dyspnea after a few minutes of walking on level ground. In addition, she noted worsening pain and morning stiffness of the wrists, knees and metacarpophalangeal (MCP) joints, with subcutaneous nodules. She…